Home・Akcijų sąrašas・ADMA Biologics Inc

ADMA Biologics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

8.26 -1.08

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.17

Max

8.39

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-4.1M 45M
Pardavimai	-25M 114M
P/E Sektoriaus vid.	12.868 62.58
Pelnas, tenkantis vienai akcijai	0.17
Pelno marža	39.59
Darbuotojai	640
EBITDA	-4.2M 61M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+123.06% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-367M 2B
Ankstesnė atidarymo kaina	9.34
Ankstesnė uždarymo kaina	8.26

Naujienos nuotaikos

By Acuity

91%

320 / 340 reitingas Healthcare

ADMA Biologics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-24 19:26; UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

2026-07-22 18:36; UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

2026-07-21 19:36; UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

2026-07-20 19:46; UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Akcijų palyginimas

Kainos pokytis

ADMA Biologics Inc Prognozė

Kainos tikslas

By TipRanks

123.06% į viršų

12 mėnesių prognozė

Vidutinis 18.67 USD 123.06%

Aukščiausias 21 USD

Žemiausias 17 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ADMA Biologics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių ADMA Biologics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

320 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.